Asper Oncogenetics is a brand name of portfolio of tests targeting tumour related conditions and predispositions.
As the early diagnosis of cancer is vital to improve the outcome of treatment and therefore preventing cancer deaths, we are offering for our customers quick services for testing most common hereditary cancers: colorectal cancer, breast and ovarian cancer as well as glioblastomas. Early diagnosis of the disease and/or estimation of disease disposition enable to reduce the number of cancer mortality cases, increase longevity and improve quality of life of patients and their families.
Most analyses of tumour related genes are performed using sequencing-based approaches, including next generation sequencing, that allow reliable, relevant and accurate detection of disease related mutations and alterations in underlying genes. Moreover, fragment analysis-based and APEX-based tests have been implemented for special conditions.
Our portfolio comprises unique up-to-date tests for implementation to individuals from different populations all over the world. Elaboration and development of tests is carried out by our experienced scientific staff in collaboration with international outstanding scientists.
BRAF gene mutation analysis
Breast and Ovarian Cancer
Familial Adenomatous Polyposis – FAP
Hereditary Non-Polyposis Colon Cancer/Lynch Syndrome – HNPCC
Lynch Syndrome and Polyposis Syndrome
Microsatellite instability – MSI
MUTYH-associated polyposis – MAP
Thiopurine S-Methyltransferase Deficiency – TPMT